TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Get Free Report) dropped 10.7% on Friday . The company traded as low as $1.18 and last traded at $1.25. Approximately 2,700 shares traded hands during mid-day trading, a decline of 35% from the average daily volume of 4,155 shares. The stock had previously closed at $1.40.
TriSalus Life Sciences Price Performance
The stock has a fifty day moving average of $1.31 and a 200-day moving average of $1.23.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
Featured Articles
- Five stocks we like better than TriSalus Life Sciences
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- How to Build the Ultimate Everything ETF Portfolio
- When to Sell a Stock for Profit or Loss
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Short Selling – The Pros and Cons
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
